ANIP
ANI Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-27/100
Last price
71.52
▼ 1.06 (1.46%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
71.52
Prev close
72.58
Day high
72.99
Day low
70.82
Volume
292.00K
Market cap
$1.64B
P/E (TTM)
15.48
52W range
69.58 – 97.00
Day trading desk
Gap from prior close
-1.46%
Prior close 72.58
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
71.52 – 71.52
Position in range
—
—
ATR (14D)
2.43
3.40% of price
Prior day high
73.40
PDH
Prior day low
71.76
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 369.29K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.51%
-3.5%
1M
+0.41%
-0.7%
3M
-15.63%
-20.2%
6M
-10.00%
-28.2%
YTD
-9.40%
-23.6%
1Y
-20.21%
-36.6%
3Y
+23.18%
-59.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
15 more panels on ANIP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-75.12K
Net selling
Buy transactions
8
35.07K shares
Sell transactions
21
110.19K shares
Net transactions
+29
Buys less sells
Sell : buy shares
3.1 : 1
Mixed
Insider-held shares
1.16M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | CAREY STEPHEN P. Chief Financial Officer |
SELL | 2.85K | $208.05K | Direct |
| Sep 15, 26 | LALWANI NIKHIL SURESH Chief Executive Officer |
SELL | 5.40K | $383.40K | Direct |
| Sep 14, 26 | COOK MEREDITH General Counsel |
SELL | 500 | $35.40K | Direct |
| Sep 11, 26 | THOMA JEANNE Director |
SELL | 1.00K | $71.53K | Direct |
| Aug 31, 26 | CAREY STEPHEN P. Chief Financial Officer |
SELL | 2.85K | $207.48K | Direct |
| Aug 25, 26 | LALWANI NIKHIL SURESH Chief Executive Officer |
SELL | 5.40K | $401.22K | Direct |
| Aug 19, 26 | GOSEBRUCH HENRY O. Director |
STOCK | 6.66K | $0 | Direct |
| Aug 13, 26 | COOK MEREDITH General Counsel |
SELL | 500 | $37.74K | Direct |
| Aug 10, 26 | GUTWERG ORI Officer |
SELL | 3.16K | $243.47K | Direct |
| Jul 29, 26 | CAREY STEPHEN P. Chief Financial Officer |
SELL | 2.85K | $231.88K | Direct |
| Jul 13, 26 | COOK MEREDITH General Counsel |
SELL | 500 | $40.92K | Direct |
| Jul 2, 26 | CAREY STEPHEN P. Chief Financial Officer |
SELL | 3.31K | $284.92K | Direct |
| Jul 2, 26 | CAREY STEPHEN P. Chief Financial Officer |
CONVERSION | 3.31K | $164.03K | Direct |
| Jun 29, 26 | CAREY STEPHEN P. Chief Financial Officer |
SELL | 2.85K | $239.74K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CAREY STEPHEN P. |
Chief Financial Officer | 168.99K | Sale |
COOK MEREDITH |
General Counsel | 73.92K | Sale |
DAVIS KRISTA |
Officer | 51.95K | Sale |
GASSERT CHAD |
Officer | 233.41K | Stock Award(Grant) |
GUTWERG ORI |
Officer | 75.53K | Sale |
HAUGHEY THOMAS J |
Director | 38.88K | Sale |
LALWANI NIKHIL SURESH |
Chief Executive Officer | 339.09K | Sale |
MUTZ CHRISTOPHER |
Officer | 91.31K | Sale |
SHANMUGAM MUTHUSAMY |
Officer and Director | 537.98K | Stock Award(Grant) |
WALSH PATRICK D |
Director | 38.43K | Sale |
Fundamentals
Market cap$1.64B
Enterprise value$1.78B
Revenue (TTM)$978.38M
Gross profit$590.98M
EBITDA$209.41M
Net income$99.60M
EPS (TTM)$4.62
Free cash flow$132.21M
Total cash$376.96M
Total debt$626.03M
Book value / share$27.87
Shares outstanding22.96M
Float19.66M
Short % of float13.21%
Dividend yield0.00%
Beta (5Y)0.50
Valuation & profitability ratios
Trailing P/E15.48
Forward P/E7.02
PEG ratio1.80
Price / sales—
Price / book2.57
EV / revenue1.82
EV / EBITDA8.51
Gross margin60.40%
Operating margin14.97%
Profit margin11.07%
Return on equity20.46%
Return on assets5.45%
Debt / equity104.83
Current ratio2.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $883.37M | $614.38M | $486.82M | $316.38M | +43.8% |
| Operating revenue | $883.37M | $614.38M | $486.82M | $316.38M | +43.8% |
| Cost of revenue | $341.31M | $250.21M | $181.51M | $138.78M | +36.4% |
| Gross profit | $542.06M | $364.17M | $305.30M | $177.60M | +48.8% |
| Research & development | $51.66M | $44.58M | $34.29M | $22.32M | +15.9% |
| Selling, general & admin | $317.75M | $249.64M | $161.70M | $124.04M | +27.3% |
| Total operating expense | $460.83M | $361.95M | $255.77M | $203.33M | +27.3% |
| Operating income | $81.23M | $2.22M | $49.53M | -$25.73M | +3,562.3% |
| Net interest income | -$20.06M | -$17.60M | -$26.94M | -$28.05M | -14.0% |
| Pre-tax income | $95.79M | -$22.21M | $19.87M | -$62.66M | +531.3% |
| Tax provision | $17.45M | -$3.69M | $1.09M | -$14.77M | +573.0% |
| Net income | $78.34M | -$18.52M | $18.78M | -$47.90M | +522.9% |
| Net income to common | $70.22M | -$20.15M | $15.47M | -$49.52M | +448.5% |
| Basic EPS | 3.50 | -1.04 | 0.86 | -3.05 | +436.5% |
| Diluted EPS | 3.32 | -1.04 | 0.85 | -3.05 | +419.2% |
| EBIT | $115.85M | -$4.61M | $46.81M | -$34.61M | +2,613.0% |
| EBITDA | $207.27M | $63.12M | $106.60M | $25.04M | +228.4% |
| Basic shares | 20.05M | 19.32M | 18.00M | 16.26M | +3.8% |
| Diluted shares | 21.23M | 19.32M | 18.19M | 16.26M | +9.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $285.58M | $144.86M | $221.12M | $48.23M | +97.1% |
| Cash & short-term investments | $294.72M | $151.17M | $221.12M | $48.23M | +95.0% |
| Accounts receivable | $281.08M | $221.73M | $162.08M | $165.44M | +26.8% |
| Inventory | $143.07M | $136.78M | $111.20M | $105.36M | +4.6% |
| Total current assets | $753.12M | $528.46M | $519.82M | $344.26M | +42.5% |
| Property, plant & equipment | $62.48M | $56.86M | $44.59M | $43.25M | +9.9% |
| Goodwill & intangibles | $542.01M | $601.82M | $237.23M | $279.86M | -9.9% |
| Total assets | $1.44B | $1.28B | $904.42M | $760.09M | +12.1% |
| Total current liabilities | $278.11M | $194.45M | $145.48M | $99.44M | +43.0% |
| Current debt | $17.27M | $9.17M | $850.00K | $850.00K | +88.3% |
| Long-term debt | $599.77M | $614.92M | $284.82M | $285.67M | -2.5% |
| Total debt | $617.03M | $624.09M | $285.67M | $286.52M | -1.1% |
| Total liabilities | $899.65M | $855.94M | $446.82M | $421.55M | +5.1% |
| Retained earnings | -$23.10M | -$100.28M | -$80.13M | -$97.29M | +77.0% |
| Shareholder equity | $540.72M | $428.53M | $457.60M | $338.54M | +26.2% |
| Working capital | $475.00M | $334.00M | $374.34M | $244.82M | +42.2% |
| Net tangible assets | -$1.28M | -$173.29M | $220.37M | $58.68M | +99.3% |
| Shares issued | 23.11M | 21.54M | 20.73M | 17.64M | +7.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $78.34M | -$18.52M | $18.78M | -$47.90M | +522.9% |
| Depreciation & amortisation | $91.42M | $67.73M | $59.79M | $59.65M | +35.0% |
| Stock-based compensation | $37.93M | $29.34M | $20.65M | $14.60M | +29.3% |
| Change in working capital | -$7.12M | -$11.19M | $24.86M | -$51.30M | +36.3% |
| Operating cash flow | $185.22M | $64.02M | $118.96M | -$31.20M | +189.3% |
| Capital expenditure | -$34.32M | -$16.95M | -$18.51M | -$16.45M | -102.4% |
| Investing cash flow | -$34.32M | -$404.72M | -$18.51M | -$15.74M | +91.5% |
| Share buybacks | -$12.21M | -$10.96M | -$4.99M | -$1.96M | -11.4% |
| Dividends paid | -$1.16M | -$1.63M | -$1.63M | -$1.63M | +28.8% |
| Financing cash flow | -$9.94M | $264.94M | $67.44M | -$5.13M | -103.8% |
| Free cash flow | $150.90M | $47.06M | $100.45M | -$47.66M | +220.6% |
| End cash position | $285.62M | $144.89M | $221.12M | $53.23M | +97.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $266.04M | $237.46M | $247.06M | $227.81M | $211.37M | +12.0% |
| Operating revenue | $266.04M | $237.46M | $247.06M | $227.81M | $211.37M | +12.0% |
| Cost of revenue | $100.16M | $93.58M | $100.27M | $93.39M | $74.61M | +7.0% |
| Gross profit | $165.89M | $143.88M | $146.79M | $134.42M | $136.76M | +15.3% |
| Research & development | $14.75M | $10.60M | $12.26M | $12.30M | $16.54M | +39.1% |
| Selling, general & admin | $91.66M | $73.66M | $82.79M | $76.66M | $81.77M | +24.4% |
| Total operating expense | $126.05M | $105.17M | $117.66M | $111.59M | $121.59M | +19.8% |
| Operating income | $39.84M | $38.71M | $29.13M | $22.83M | $15.17M | +2.9% |
| Net interest income | -$3.64M | -$3.77M | -$4.41M | -$4.73M | -$5.44M | +3.5% |
| Pre-tax income | $37.10M | $40.22M | $31.48M | $33.80M | $10.53M | -7.8% |
| Tax provision | $12.39M | $10.73M | $3.99M | $7.18M | $1.98M | +15.4% |
| Net income | $24.71M | $29.49M | $27.49M | $26.62M | $8.55M | -16.2% |
| Net income to common | $23.00M | $29.49M | $20.53M | $26.27M | $7.32M | -22.0% |
| Basic EPS | 1.09 | 1.31 | 1.24 | 1.19 | 0.37 | -16.8% |
| Diluted EPS | 1.05 | 1.28 | 1.18 | 1.13 | 0.36 | -18.0% |
| EBIT | $40.73M | $43.99M | $35.89M | $38.53M | $15.96M | -7.4% |
| EBITDA | $60.37M | $64.91M | $58.50M | $61.16M | $39.24M | -7.0% |
| Basic shares | 21.16M | 20.91M | 20.69M | 20.07M | 19.83M | +1.2% |
| Diluted shares | 21.91M | 21.54M | 21.77M | 21.09M | 20.31M | +1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $360.21M | $311.18M | $285.58M | $262.61M | $217.80M | +15.8% |
| Cash & short-term investments | $375.84M | $326.06M | $294.72M | $271.47M | $223.51M | +15.3% |
| Accounts receivable | $274.47M | $255.43M | $281.08M | $252.62M | $225.65M | +7.5% |
| Inventory | $143.15M | $143.47M | $143.07M | $146.47M | $138.31M | -0.2% |
| Total current assets | $825.43M | $747.08M | $753.12M | $698.40M | $602.63M | +10.5% |
| Property, plant & equipment | $73.22M | $67.11M | $62.48M | $63.56M | $59.25M | +9.1% |
| Goodwill & intangibles | $512.34M | $529.64M | $542.01M | $562.30M | $580.85M | -3.3% |
| Total assets | $1.49B | $1.42B | $1.44B | $1.41B | $1.34B | +5.1% |
| Total current liabilities | $283.65M | $239.51M | $278.11M | $270.56M | $236.84M | +18.4% |
| Current debt | $21.33M | $19.30M | $17.27M | $15.24M | $13.22M | +10.5% |
| Long-term debt | $589.16M | $594.46M | $599.77M | $605.07M | $608.35M | -0.9% |
| Total debt | $610.49M | $613.76M | $617.03M | $620.31M | $621.56M | -0.5% |
| Total liabilities | $896.90M | $859.67M | $899.65M | $902.34M | $881.39M | +4.3% |
| Retained earnings | $31.10M | $6.39M | -$23.10M | -$50.59M | -$76.86M | +386.5% |
| Shareholder equity | $597.21M | $562.30M | $540.72M | $505.82M | $461.61M | +6.2% |
| Working capital | $541.78M | $507.57M | $475.00M | $427.85M | $365.80M | +6.7% |
| Net tangible assets | $84.88M | $32.66M | -$1.28M | -$56.48M | -$119.25M | +159.9% |
| Shares issued | 22.97M | 23.76M | 23.11M | 23.08M | 22.32M | -3.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $24.71M | $29.49M | $27.49M | $26.62M | $8.55M | — | -16.2% |
| Depreciation & amortisation | $19.64M | $20.92M | $22.61M | $22.63M | $23.28M | — | -6.1% |
| Stock-based compensation | $11.41M | $10.19M | $9.77M | $9.69M | $9.60M | — | +11.9% |
| Change in working capital | $6.40M | $382.00K | -$26.85M | -$17.84M | $36.24M | — | +1,575.4% |
| Operating cash flow | $56.67M | $58.38M | $30.37M | $44.05M | $75.81M | — | -2.9% |
| Capital expenditure | -$3.05M | -$11.32M | -$1.40M | -$6.16M | -$6.91M | — | +73.0% |
| Investing cash flow | -$3.05M | -$11.32M | -$1.40M | -$6.16M | -$6.91M | — | +73.0% |
| Share buybacks | — | -$19.75M | — | — | — | -$10.00M | — |
| Dividends paid | $0 | $0 | $0 | -$344.00K | -$407.00K | — | — |
| Financing cash flow | -$4.65M | -$21.62M | -$4.64M | $6.34M | -$1.75M | — | +78.5% |
| Free cash flow | $53.62M | $47.05M | $28.96M | $37.89M | $68.90M | — | +14.0% |
| End cash position | $360.25M | $311.21M | $285.62M | $262.65M | $217.83M | — | +15.8% |
Options analytics
Put / call volume
0.69
Call-heavy session
Put / call open interest
1.33
Positioning, not flow
Max pain
95.00
+32.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
45
Contracts, this expiry
Put volume
31
Contracts, this expiry
Heaviest call OI
110.00
6 contracts
Heaviest put OI
95.00
5 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.04 | 2.21 | +8.2% |
| Mar 2026 | 1.30 | 2.05 | +57.8% |
| Dec 2025 | 1.98 | 2.33 | +17.8% |
| Sep 2025 | 1.77 | 2.04 | +15.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.18 | 9 | $280.20M | +23.0% |
| Next quarter | 2.82 | 9 | $319.27M | +29.2% |
| Current year | 9.26 | 9 | $1.10B | +24.9% |
| Next year | 10.17 | 9 | $1.22B | +10.8% |
Analyst targets & ownership
Mean target$105.78
High target$121.00
Low target$85.00
Implied upside47.90%
Analyst count9
ConsensusBUY
Strong buy / Buy3 / 4
Hold2
Sell / Strong sell0 / 0
Held by insiders5.42%
Held by institutions107.26%
Institutions holding418
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
73.18
-2.27% from price
SMA 20
73.43
-2.60% from price
SMA 50
75.07
-4.74% from price
SMA 100
78.04
-8.36% from price
SMA 200
78.42
-8.80% from price
EMA 12
73.12
-2.19% from price
EMA 26
73.74
-3.01% from price
EMA 50
74.97
-4.61% from price
RSI (14)
41.6
Neutral
MACD (12,26,9)
-0.62
Hist -0.17
ATR (14)
2.43
3.40% of price
Realised vol 30D
27.6%
Annualised
Bollinger upper
78.00
20, 2σ
Bollinger lower
68.86
20, 2σ
50 / 200 cross
Death
75.07 vs 78.42
Trend bias
Below 200
-8.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.24
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
27.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.4%
Peak to trough
Max drawdown 5Y
-59.4%
Peak to trough
ATR 14
2.43
3.40% of price
Beta (reported)
0.50
5Y monthly, from filing
Short interest
Shares short
2.49M
Prior 3.42M
Change vs prior
-27.2%
Shorts covering
% of float
13.21%
Elevated
% of shares out
10.84%
Against total outstanding
Days to cover
7.0
Crowded exit
Float
19.66M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Oppenheimer | INITIATED | — | Perform |
| Aug 10, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Hold | Hold |
| Jul 17, 26 | Canaccord Genuity | INITIATED | — | Hold |
| Jul 10, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jan 16, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Dec 9, 25 | Barclays | INITIATED | — | Overweight |
| Nov 10, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| Oct 9, 25 | Truist Securities | MAINTAINED | Hold | Hold |
| Sep 24, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 8, 25 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:6
Split dateJul 18, 2013
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-24
Periodic Financial Reports
10-Q · 2026-08-07
Offering Registrations
S-8 · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-13
Periodic Financial Reports
10-Q · 2026-05-08
Annual Report to Shareholders
ARS · 2026-04-09
Corporate Changes & Voting Matters
8-K · 2026-04-07
Headlines
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
StockStory · 23h ago
1 Small-Cap Stock for Long-Term Investors and 2 We Ignore
StockStory · 6d ago
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
GlobeNewswire · 7d ago
3 Profitable Stocks Worth Investigating
StockStory · 8d ago
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Zacks · 9d ago
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
StockStory · 13d ago
Sector Update: Healthcare Stocks Mixed Premarket Wednesday
MT Newswires · 14d ago
ANI Pharmaceuticals Wins FDA Approval for Generic Everolimus Tablets
MT Newswires · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.